This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Uloric

Takeda Pharmaceutical Company Ltd

Drug Names(s): febuxostat, TMX-67, Adenuric (EU), TEI-6720, Feburic (JP), febuxostat XR, TMX-67 XR

Description: Uloric (febuxostat) is a non-purine, selective inhibitor of xanthine oxidase.

Deal Structure: TAP and Teijin
In October 1999, TAP Pharmaceuticals in-licensed febuxostat from Teijin Limited. As part of the agreement, TAP will develop febuxostat in the United States and has the right to market it in the United States and Canada. TAP is a joint venture between Abbott Laboratories and Takeda.

In March 2008, Takeda Pharmaceutical and Abbott concluded their TAP Pharmaceutical Products (TAP) joint venture.

Ipsen and Teijin
In July 2003, Ipsen entered into a research and development partnership with Teijin. This partnership covers the development and marketing by Ipsen in Europe (i.e. in the European Union and countries located to the west of Russia, including Russia) of Febuxostat. Teijin has granted Ipsen exclusive rights in Europe to develop and market Febuxostat. Febuxostat's development costs will be borne by Ipsen, except for the cost of conducting clinical trials that may be requested by the regulatory authorities prior to the registration of...See full deal structure in Biomedtracker

Partners: AbbVie Inc. Teijin Pharma Limited Ipsen SA The Menarini Group Astellas Pharma, Inc.


Uloric News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug